Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C?

Journal of Nephrology

Volumn 20, Issue 3, 2007, Pages 350-356

  Ahmed, Muhammad S ^a   Wong, Christopher F ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Cryoglobulinemia; Hepatitis C; Rituximab; Vasculitis

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIN; GABAPENTIN; IMMUNOGLOBULIN; INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PREDNISOLONE; RIBAVIRIN; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ARTICLE; BRADYCARDIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; CRYPTOCOCCOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE RESISTANCE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FOLLOW UP; HEPATITIS C; HERPES SIMPLEX; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MONOTHERAPY; NEPHROTIC SYNDROME; NEUTROPENIA; PLASMAPHERESIS; PROTEINURIA; RANDOMIZATION; RELAPSE; REMISSION; SEX RATIO; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CRYOGLOBULINEMIA; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS;

EID: 35348835457     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999; 13: 1315-49.
2. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum 1999; 42: 2507-16.
3. De vita S, De Re V, Gasparotto D, Ballare M, Pivetta B, Ferraccioli G, Pileri S, Boiocchi M, Monteverde A. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: Arthritis Rheum 2000; 43: 94-102.
4. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54: 650-71.
5. Fabrizi F, Colucci P, Ponticelli C, Locatelli F. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 2002; 22: 309-18.
6. Tarantino A, Campise M, Banfi G, Confalonied R, Bucci A, Montoli A, Colasanti G, Damilano I, D'Amico G, Minetti L, Ponticelli C. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-23.
7. Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephrities. Kidney Int 2006; 69: 436-9.
8. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101: 3818-26.
9. Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, Costanzo P, Giachino O, MA2M G, Sena LM. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-61.
10. Ramos-Caslas M, Trejo O, Garcia-Carrasco M, Cervera R, Font J. Mixed cryoglobulinaemia: new concept. Lupus 2000; 9: 83-91.
11. Fornasieri A, Li M, Armelloni S, de Septis CP, Schlaffino E, Sinico RA, Schmid C, D'Amico G. Glomerulonephritis induced by human IgMK-IgG cryoglobulins in mice. Lab Invest 1993; 69: 531-40.
12. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
13. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ung MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Mad 1998; 339: 1485-92.
14. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G, Tanzi E, Zanetti A. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Mad 1994; 330: 751-6.
15. Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, Lauletta G, Rizzi R. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84: 3336-43.
16. Cacoub P, Saadoun D, Limal N, Sena D, Lidove O, Piette JC. Pegylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005; 52: 911-5.
17. Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, Carniello G, Virgolini L, Tirelli U, Pozzato G. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42: 632-8.
18. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45.
19. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34. Epub 2003 Jan 30.
20. Wong C. Rituximab in refractory antineutrophil cytoplasmic antibody associated vasculitis: what the current evidence? Nephrol Dial Transplant 2007; 22: 32-6.
21. Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, Grillo-Lopez AJ. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10: 1525-7.
22. Saleh MN, Gutheli J, Moore M, Bunch PW, Butler J, Kunkel L, Grillo-Lopez AJ, LoBuglio AF. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000; 27 (Suppl 12): 99-103.
23. Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001; 97: 3995-7.
24. Fra GP, Avanzi GC, Bartoll E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12: 783-7.
25. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14: 1851-7.
26. Lavine TD, Pestronk A. IgM anti body-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999; 52: 1701-4.
27. Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000; 55: 1062-3.
28. Quartuccio L, Sorado G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45: 842-6.
29. Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, Guitard J, Lavayssiere L, Oksman F, Durand D, Rostaing L. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006; 38: 2308-10.
30. Pekow J, Chung RT. Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab. J Clin Gastroenterol 2006; 40: 450.
31. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, Peters SO, Gutzeft O, Arlt AC, Solbach W, Gross WL. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003; 62: 1230-3.
32. Koukoulaki M, Sumith C, Abeygunasekara SC, Smith KG, Jayne DR. Remission of refractory hepatits C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant 2005; 20: 213-6.
33. Bastard O, Cruzado JM, Ercilla G, Goma M, Torras J, Seron D, Rama I, Ibernon M, Vinas O, Carrera M, Grinyo JM. Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant 2006; 21: 2320-4. Epub 2006 Jun.
34. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglabulinemia with renal and cardiac failure. Am J Kidney Dis 2004; 43: e34-8.
35. Bruchfield A, Saadoun D, Cacoub P. Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: anti-viral therapy vs rituximab. Rheumatology (Oxford) 2006; 45: 783-4.